Crestline Management’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Crestline Management’s Portfolio TARO Stock Details TARO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-37,000	Closed	-$2.79M	–	94
2019 Q3	$2.79M	Buy	+37,000	New	+$3M	0.45%	39

Other funds holding TARO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Crestline Management's TARO Position: Q4 2019 in Review

Crestline Management sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q4 2019, closing a stake of 37,000 shares — an estimated $2.79M sold.

Crestline Management first reported a position in TARO in Q3 2019 and held it in 1 quarter. The position peaked at $2.79M in Q3 2019. 94 funds tracked by Wall St. Rank hold TARO as of Q4 2019.

Crestline Management reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q4 2019 after selling out during the quarter.
Crestline Management sold 37,000 Taro Pharmaceutical Industries Ltd. shares in Q4 2019, an estimated $2.79M.
Crestline Management first reported a position in Taro Pharmaceutical Industries Ltd. in Q3 2019 and held it in 1 quarter.
Crestline Management's Taro Pharmaceutical Industries Ltd. position peaked at $2.79M in Q3 2019.
94 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q4 2019.

Based on Crestline Management's 13F filing for Q4 2019, filed 12 Feb 2020.